Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Pediátricos / Tumor de Wilms / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de julio del 2002
1
UI - 12086755
AU - Reeve AE; Becroft DM; Morison IM; Fukuzawa R
TI -
Insulin-like growth factor-II imprinting in cancer.
SO - Lancet 2002 Jun 15;359(9323):2050-1
AD - Cancer Genetics Laboratory, Department of Biochemistry, University of
Otago, Dunedin, New Zealand. a.reeve@otago.nac.nz
2
UI - 12082525
AU - Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
TI -
Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
SO - Oncogene 2002 May 2;21(19):2948-60
AD - Institute for Molecular Bioscience, The University of Queensland, St
Lucia, Brisbane, QLD 4072, Australia.
The Wilms' tumour suppressor gene, WT1, encodes multiple nuclear protein
isoforms, all containing four C-terminal zinc finger motifs. WT1
proteins can both activate and repress putative target genes in vitro,
although the in vivo relevance of these putative target genes is often
unverified. WT1 mutations can result in Wilms' tumour and the
Denys-Drash Syndrome (DDS) of infantile nephropathy, XY
pseudohermaphroditism and predisposition to Wilms' tumour. We have
established stable transfectants of the mouse mesonephric cell line,
M15, which express WT1 harbouring a common DDS point mutation (R394W). A
comparison of the expression profiles of M15 and transfectant C2A was
performed using Nylon-based arrays. Very few genes showed differential
expression. However Wnt-4, a member of the Wnt gene family of secreted
glycoproteins, was downregulated in C2A and other similar clones.
Doxycycline induction of WT1-A or WT1-D expression in HEK293 stable
transfectants also elicited an elevation in Wnt4 expression. Wnt4 is
critical for the mesenchyme-to-epithelial transition during kidney
development, making it an attractive putative WT1 target. We have mapped
human Wnt-4 gene to chromosome 1p35-36, a region of frequent LOH in WT,
have characterized the genomic structure of the human Wnt-4 gene and
isolated 9 kb of immediate promoter. While several potential WT1 binding
sites exist within this promoter, reporter analysis does not strongly
support the direct regulation of Wnt4 by WT1. We propose that Wnt-4
regulation by WT1 occurs at a more distant promoter or enhancer site, or
is indirect.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Survivorship care can help cancer survivors live healthier, fuller lives after treatment. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

